Cargando…

Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a constantly evolving virus, resulting in an increased burden on the existing COVID-19 vaccines. Healthcare workers (HCWs) are the first line of defense against the coronavirus disease 2019 (COVID-19) pandemic and have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammad, Noha M., Kadry, Heba M., Malek, Mai M., Bahgat, Shereen Mohamed, Abdelsalam, Noha M., Afifi, Amira Hamed Mohamed, Abo-alella, Doaa Alhussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608749/
https://www.ncbi.nlm.nih.gov/pubmed/36298571
http://dx.doi.org/10.3390/vaccines10101706
_version_ 1784818843839889408
author Hammad, Noha M.
Kadry, Heba M.
Malek, Mai M.
Bahgat, Shereen Mohamed
Abdelsalam, Noha M.
Afifi, Amira Hamed Mohamed
Abo-alella, Doaa Alhussein
author_facet Hammad, Noha M.
Kadry, Heba M.
Malek, Mai M.
Bahgat, Shereen Mohamed
Abdelsalam, Noha M.
Afifi, Amira Hamed Mohamed
Abo-alella, Doaa Alhussein
author_sort Hammad, Noha M.
collection PubMed
description Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a constantly evolving virus, resulting in an increased burden on the existing COVID-19 vaccines. Healthcare workers (HCWs) are the first line of defense against the coronavirus disease 2019 (COVID-19) pandemic and have been prioritized among the risk categories receiving the COVID-19 vaccine. This work aimed to investigate the maintenance of antibody response of the Oxford–AstraZeneca vaccine (ChAdOx1/nCoV-19). Methods: Anti-spike immunoglobulin G (IgG) was measured at baseline point (immediately prior to vaccination) and 12- and 24-week (w) points following vaccination. Adverse reactions to the vaccine were reported. Participants were followed up for the incidence of COVID-19 during the 12 w interval between vaccination doses for 24 w after the second dose. Results: A total of 255 HCWs participated in the study. Prior to vaccination, 54.1% experienced COVID-19, 88.2% were seropositive after the first dose, while seropositivity reached 95.7% after the second dose. Following the first and second doses, the anti-spike IgG serum level was significantly higher in subjects with past COVID-19 than in others (p < 0.001 and =0.001, respectively). Conclusions: The Oxford–AstraZeneca vaccine is generally safe and provides a highly effective long-term humoral immune response against the Delta and Omicron variants of SARS-CoV-2.
format Online
Article
Text
id pubmed-9608749
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96087492022-10-28 Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study Hammad, Noha M. Kadry, Heba M. Malek, Mai M. Bahgat, Shereen Mohamed Abdelsalam, Noha M. Afifi, Amira Hamed Mohamed Abo-alella, Doaa Alhussein Vaccines (Basel) Article Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a constantly evolving virus, resulting in an increased burden on the existing COVID-19 vaccines. Healthcare workers (HCWs) are the first line of defense against the coronavirus disease 2019 (COVID-19) pandemic and have been prioritized among the risk categories receiving the COVID-19 vaccine. This work aimed to investigate the maintenance of antibody response of the Oxford–AstraZeneca vaccine (ChAdOx1/nCoV-19). Methods: Anti-spike immunoglobulin G (IgG) was measured at baseline point (immediately prior to vaccination) and 12- and 24-week (w) points following vaccination. Adverse reactions to the vaccine were reported. Participants were followed up for the incidence of COVID-19 during the 12 w interval between vaccination doses for 24 w after the second dose. Results: A total of 255 HCWs participated in the study. Prior to vaccination, 54.1% experienced COVID-19, 88.2% were seropositive after the first dose, while seropositivity reached 95.7% after the second dose. Following the first and second doses, the anti-spike IgG serum level was significantly higher in subjects with past COVID-19 than in others (p < 0.001 and =0.001, respectively). Conclusions: The Oxford–AstraZeneca vaccine is generally safe and provides a highly effective long-term humoral immune response against the Delta and Omicron variants of SARS-CoV-2. MDPI 2022-10-12 /pmc/articles/PMC9608749/ /pubmed/36298571 http://dx.doi.org/10.3390/vaccines10101706 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hammad, Noha M.
Kadry, Heba M.
Malek, Mai M.
Bahgat, Shereen Mohamed
Abdelsalam, Noha M.
Afifi, Amira Hamed Mohamed
Abo-alella, Doaa Alhussein
Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
title Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
title_full Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
title_fullStr Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
title_full_unstemmed Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
title_short Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study
title_sort maintenance of antibody response in egyptian healthcare workers vaccinated with chadox1 ncov-19 vaccine during delta and omicron variants pandemic: a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608749/
https://www.ncbi.nlm.nih.gov/pubmed/36298571
http://dx.doi.org/10.3390/vaccines10101706
work_keys_str_mv AT hammadnoham maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy
AT kadryhebam maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy
AT malekmaim maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy
AT bahgatshereenmohamed maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy
AT abdelsalamnoham maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy
AT afifiamirahamedmohamed maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy
AT aboalelladoaaalhussein maintenanceofantibodyresponseinegyptianhealthcareworkersvaccinatedwithchadox1ncov19vaccineduringdeltaandomicronvariantspandemicaprospectivestudy